Skip to main content
James Jarvis on Muck Rack

James Jarvis

Verified
East Coast United States, Washington, D.C.
As seen in: Inside Health Policy, Medium, Aol, MDPI, The Hill, GamesRadar+, blogs.lse.ac.uk, Cell Press, Bangor Daily News, WTOP News (Washington, DC), City A.M. and
Inside Health Policy reporter covering FDA & Georgetown journalism prof. Got a news tip? Email jjarvis@iwpnews.com/jjarvis1015@gmail.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with James

Contact James, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pallone Asks GAO If FDA User Fee Spending On DOGE Layoffs Legal

|
By James Jarvis Verified
| Inside Health Policy Verified
House Energy & Commerce ranking Democrat Frank Pallone (NJ) is asking congressional investigators to determine whether FDA unlawfully used industry user fee funds to cover severance and other costs stemming from the Trump administration’s 2025 workforce cuts ahead of next year’s user fee reauthorization.
Open in Who Shared Issue with article?

FDA Adds Detail To Psychedelic Trial Guidance Amid Broader Federal Access Push

|
By James Jarvis Verified
| Inside Health Policy Verified
As part of a broader federal effort to accelerate development of and access to psychedelic drugs, FDA this week released guidance giving sponsors more detailed recommendations for designing trials that account for the drugs’ noticeable effects and produce reliable evidence of safety and effectiveness.
Open in Who Shared View Duplicates (2) Issue with article?

White House Presses House GOP To Rework Hemp Ban As DEA Rescheduling Hearing Opens

|
By James Jarvis Verified
| Inside Health Policy Verified
A top White House budget official is urging House Speaker Mike Johnson (R-LA) to support a legislative fix that would soften, or at least delay, restrictions on hemp-derived cannabinoid products set to take effect later this year under the Republican-backed One Big Beautiful Bill Act.
Open in Who Shared Issue with article?
See all 2,315 licensed articles (2,545 Total)